The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS).
Gary K. Schwartz
Consultant or Advisory Role - Pfizer (I)
Honoraria - ImClone Systems
William D. Tap
No relevant relationships to disclose
Li-Xuan Qin
No relevant relationships to disclose
Michael B. Livingston
No relevant relationships to disclose
Samir D. Undevia
No relevant relationships to disclose
Bartosz Chmielowski
No relevant relationships to disclose
Mark Agulnik
No relevant relationships to disclose
Scott Schuetze
No relevant relationships to disclose
Damon R. Reed
No relevant relationships to disclose
Scott H. Okuno
No relevant relationships to disclose
Joseph A. Ludwig
No relevant relationships to disclose
Kenneth R. Hande
No relevant relationships to disclose
Petra Rietschel
No relevant relationships to disclose
Andrew S. Kraft
No relevant relationships to disclose
Douglas Adkins
No relevant relationships to disclose
Bruce Brockstein
No relevant relationships to disclose
Vincent Yim
No relevant relationships to disclose
Christiana Bitas
No relevant relationships to disclose
Cristina Antonescu
No relevant relationships to disclose
Robert G. Maki
Consultant or Advisory Role - ImClone Systems; Pfizer